UPDATE 1-U.S. FDA approves Otsuka and Lundbeck's schizophrenia treatment

July 10 (Reuters) - The U.S. Food and Drug Administration approved Danish drugmaker H. Lundbeck A/S and Japan's Otsuka Pharmaceutical Co Ltd's Rexulti, an anti-psychotic drug used to treat schizophrenia.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.